ADC Therapeutics (ADCT) Change in Accured Expenses (2023 - 2026)

ADC Therapeutics (ADCT) has reported Change in Accured Expenses for 4 consecutive years, with -$3.2 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses rose 84.57% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 268.59% YoY) and the FY2025 annual result came in at -$7.4 million, down 166.61% from the prior year.
• Change in Accured Expenses retreated to -$3.2 million in Q1 2026 per ADCT's latest filing, from $2.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for ADCT reached as high as $12.0 million in Q2 2025 and fell as low as -$20.6 million in Q1 2025.
• A 4-year average of -$1.0 million and a median of -$799000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses surged 1172.64% — and 2025, when it slumped 482.3%.
• Year by year, Change in Accured Expenses stood at $2.0 million in 2023, then soared by 475.61% to $11.3 million in 2024, then tumbled by 82.54% to $2.0 million in 2025, then tumbled by 261.25% to -$3.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.2 million, $2.0 million, and -$799000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.